Vmbook Online ordering
Intellipharmaceutics Internati
Intellipharmaceutics International Inc. is a public drug delivery company that is focused on the development and manufacturing of pharmaceutical products based on its proprietary drug delivery technologies. The company was founded in 2006 and is headquartered in Toronto, Canada. Its American Depository Shares (ADS) are listed on the NASDAQ stock exchange in the United States under the ticker symbol "IPCI".
Intellipharmaceutics is focused on the development of improved pharmaceutical products, particularly those that address unmet medical needs and/or offer significant advantages over existing products. The company's product pipeline includes both generic and branded products, and it utilizes a number of different drug delivery technologies, such as extended-release and sustained-release formulations, to improve the efficacy and safety of its products.
The company has a number of products in various stages of development, including both generic and branded products. Some of its key products in development include:
* Generic versions of several blockbuster drugs, including OxyContin and Opana ER, which are used to treat moderate to severe pain.
* Branded products, such as Rexista, which is an abuse-deterrent formulation of oxycodone, and a number of other products that are in various stages of development.
Intellipharmaceutics has a number of partnerships and collaborations with other pharmaceutical companies, including Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, and Dr. Reddy's Laboratories, among others. These collaborations typically involve the development and commercialization of generic versions of brand-name drugs.
The company's financial performance has been mixed in recent years, with revenue and net income fluctuating from year to year. However, the company has managed to generate positive cash flow in recent years, which has allowed it to continue investing in the development of its product pipeline.
Intellipharmaceutics is led by a team of experienced pharmaceutical executives, including its CEO, Dr. Isa Odidi, who co-founded the company and has served as its CEO since its inception. The company's management team has a strong track record of developing and commercializing pharmaceutical products, and it is well-positioned to continue growing its business in the coming years.
It is worth noting that as a public company, the stock price of Intellipharmaceutics is subject to the same market forces and economic conditions as any other publicly traded company, and as such, the stock price can be volatile. Investors should carefully consider their own investment objectives and risk tolerance before investing in the stock. As with any investment, it is recommended to do thorough research and seek the advice of a qualified financial professional before making any investment decisions.